Crispr Therapeutics AG (CRSP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.10B
Last updated: Nov 17, 2026 at 11:05 AM ET
Crispr Therapeutics AG (CRSP) Earnings: Report Dates and Results
Crispr Therapeutics AG (CRSP) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Crispr Therapeutics AG reported EPS of -$1.15, below the -$1.06 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CRSP has an expected report date of Feb 10, 2027.
Earnings History
Of the 39 quarters below that had an estimate, CRSP beat 18, missed 20 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $12.67M, up 1325.2% from $889000 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.15 | -$1.06 | -$1.50 - -$0.46 | -8.49% | Miss | N/A | 17 | 0 up, 1 down | Nov 2, 2026 | $12.67M |
| Jun 30, 2026 | -$0.94 | -$1.10 | -$1.44 - -$0.81 | +14.55% | Beat | N/A | 17 | 0 up, 1 down | Aug 3, 2026 | $10.18M |
| Mar 31, 2026 | -$1.28 | -$1.23 | -$1.51 - -$0.81 | -4.07% | Miss | N/A | 19 | 1 up, 1 down | May 4, 2026 | $1.46M |
| Dec 31, 2025 | -$1.37 | -$1.23 | -$1.67 - -$0.98 | -11.38% | Miss | N/A | 16 | 5 up, 7 down | Feb 12, 2026 | $864000 |
| Sep 30, 2025 | -$1.17 | -$1.29 | -$1.67 - -$0.96 | +9.30% | Beat | N/A | 14 | 1 up, 0 down | Nov 10, 2025 | $889000 |
| Jun 30, 2025 | -$1.29 | -$1.40 | -$1.78 - -$0.93 | +7.86% | Beat | N/A | 19 | 1 up, 1 down | Aug 4, 2025 | $892000 |
| Mar 31, 2025 | -$1.58 | -$1.28 | -$1.74 - -$0.74 | -23.44% | Miss | N/A | 17 | 0 up, 2 down | May 6, 2025 | $865000 |
| Dec 31, 2024 | -$0.44 | -$1.19 | -$1.93 - -$0.74 | +62.89% | Beat | -140.0% | 23 | 1 up, 0 down | Feb 11, 2025 | $35.69M |
| Sep 30, 2024 | -$1.01 | -$1.40 | -$1.90 - -$0.43 | +27.86% | Beat | N/A | 23 | 1 up, 0 down | Nov 5, 2024 | $602000 |
| Jun 30, 2024 | -$1.49 | -$1.43 | -$1.91 - -$1.08 | -4.20% | Miss | N/A | 22 | 0 up, 0 down | Aug 5, 2024 | $517000 |
| Mar 31, 2024 | -$1.43 | -$1.33 | -$2.07 - $0.80 | -7.52% | Miss | N/A | 19 | 2 up, 0 down | May 8, 2024 | $504000 |
| Dec 31, 2023 | $1.10 | $0.05 | -$2.09 - $1.25 | N/A | N/A | N/A | 22 | 1 up, 2 down | Feb 21, 2024 | $201.21M |
| Sep 30, 2023 | -$1.41 | -$1.95 | -$2.37 - -$0.73 | +27.69% | Beat | N/A | 22 | 1 up, 0 down | Nov 6, 2023 | N/A |
| Jun 30, 2023 | -$0.98 | -$2.10 | -$2.32 - -$1.56 | +53.33% | Beat | N/A | 23 | 0 up, 0 down | Aug 7, 2023 | $70.00M |
| Mar 31, 2023 | -$0.67 | -$1.64 | -$2.39 - -$0.56 | +59.15% | Beat | N/A | 20 | 0 up, 0 down | May 8, 2023 | $100.00M |
| Dec 31, 2022 | -$1.41 | -$2.30 | -$2.66 - -$1.33 | +38.70% | Beat | N/A | 22 | 0 up, 0 down | Feb 21, 2023 | $6000 |
| Sep 30, 2022 | -$2.24 | -$2.24 | -$2.58 - -$1.81 | 0.00% | In line | N/A | 22 | 0 up, 0 down | Nov 1, 2022 | $94000 |
| Jun 30, 2022 | -$2.40 | -$2.21 | -$2.48 - -$1.89 | -8.60% | Miss | -125.4% | 21 | 0 up, 1 down | Aug 8, 2022 | $158000 |
| Mar 31, 2022 | -$2.32 | -$1.97 | -$2.28 - -$1.61 | -17.77% | Miss | N/A | 19 | 0 up, 0 down | May 9, 2022 | $940000 |
| Dec 31, 2021 | -$1.84 | -$1.78 | -$2.17 - -$1.38 | -3.37% | Miss | N/A | 21 | 0 up, 0 down | Feb 15, 2022 | $12.90M |
| Sep 30, 2021 | -$1.67 | -$1.76 | -$2.00 - -$1.39 | +5.11% | Beat | N/A | 21 | N/A | Nov 3, 2021 | $824000 |
| Jun 30, 2021 | $9.44 | $3.12 | -$1.61 - $10.43 | +202.56% | Beat | N/A | 18 | N/A | Jul 29, 2021 | $900.70M |
| Mar 31, 2021 | -$1.51 | -$1.47 | -$1.64 - -$1.20 | -2.72% | Miss | N/A | 19 | N/A | Apr 27, 2021 | $539000 |
| Dec 31, 2020 | -$1.50 | -$1.27 | -$1.40 - -$0.70 | -18.11% | Miss | -394.1% | 18 | N/A | Feb 16, 2021 | $370000 |
| Sep 30, 2020 | -$1.32 | -$1.19 | -$1.30 - -$0.87 | -10.92% | Miss | -155.0% | 17 | N/A | Oct 28, 2020 | $148000 |
| Jun 30, 2020 | -$1.30 | -$0.99 | -$1.32 - -$0.76 | -31.31% | Miss | N/A | 15 | N/A | Jul 27, 2020 | $44000 |
| Mar 31, 2020 | -$1.15 | -$1.04 | -$1.20 - -$0.77 | -10.58% | Miss | N/A | 15 | N/A | Apr 28, 2020 | $157000 |
| Dec 31, 2019 | $0.51 | -$0.63 | -$1.36 - $0.23 | +180.95% | Beat | N/A | 14 | N/A | Feb 12, 2020 | $77.02M |
| Sep 30, 2019 | $2.40 | $1.79 | N/A | +34.08% | Beat | N/A | 9 | N/A | Oct 28, 2019 | $211.93M |
| Jun 30, 2019 | -$1.01 | -$0.90 | -$1.08 - -$0.73 | -12.22% | Miss | N/A | 10 | N/A | Jul 29, 2019 | $318000 |
| Mar 31, 2019 | -$0.93 | -$0.90 | -$1.01 - -$0.79 | -3.33% | Miss | N/A | 11 | N/A | Apr 29, 2019 | $328000 |
| Dec 31, 2018 | -$0.92 | -$0.78 | -$0.89 - -$0.57 | -17.95% | Miss | -27158.8% | 10 | N/A | Feb 25, 2019 | $115000 |
| Sep 30, 2018 | -$1.07 | -$0.74 | -$0.85 - -$0.59 | -44.59% | Miss | N/A | 9 | N/A | Nov 7, 2018 | $563000 |
| Jun 30, 2018 | -$0.82 | -$0.64 | -$0.71 - -$0.59 | -28.13% | Miss | N/A | 6 | N/A | Aug 7, 2018 | $1.09M |
| Mar 31, 2018 | -$0.62 | -$0.67 | -$0.74 - -$0.60 | +7.46% | Beat | N/A | 8 | N/A | May 8, 2018 | $1.36M |
| Dec 31, 2017 | $0.00 | -$0.67 | -$0.77 - -$0.64 | +100.51% | Beat | -99.8% | 6 | N/A | Mar 8, 2018 | $32.33M |
| Sep 30, 2017 | -$0.62 | -$0.60 | -$0.68 - -$0.51 | -3.33% | Miss | N/A | 5 | N/A | Nov 8, 2017 | $2.39M |
| Jun 30, 2017 | -$0.56 | -$0.62 | -$0.70 - -$0.56 | +9.68% | Beat | N/A | 4 | N/A | Aug 10, 2017 | $3.58M |
| Mar 31, 2017 | -$0.54 | -$0.65 | N/A | +16.92% | Beat | N/A | N/A | N/A | May 11, 2017 | $2.70M |
| Dec 31, 2016 | $1.42 | -$0.49 | N/A | +389.80% | Beat | N/A | N/A | N/A | Mar 10, 2017 | $2.34M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$5.41, after -$4.37 the year before. It was $1.05 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$5.41 | N/A |
| Dec 31, 2024 | -$4.37 | N/A |
| Dec 31, 2023 | -$1.96 | N/A |
| Dec 31, 2022 | -$8.37 | -289.4% |
| Dec 31, 2021 | $4.42 | N/A |
| Dec 31, 2020 | -$5.27 | -643.3% |
| Dec 31, 2019 | $0.97 | N/A |
| Dec 31, 2018 | -$3.43 | N/A |
| Dec 31, 2017 | -$1.72 | -263.5% |
| Dec 31, 2016 | $1.05 | N/A |
Frequently Asked Questions About CRSP
When is Crispr Therapeutics AG's next earnings date?
Crispr Therapeutics AG's next earnings report is expected for Feb 10, 2027.
Did CRSP beat earnings estimates last quarter?
No. Crispr Therapeutics AG reported EPS of -$1.15 for the quarter ended Sep 30, 2026, below the -$1.06 estimate by 8.49%.
What EPS do analysts expect from CRSP next quarter?
The consensus EPS estimate for Crispr Therapeutics AG for the quarter ending Dec 31, 2026 is -$1.26 from 22 analysts, with estimates from -$2.10 to -$0.79.
How often does CRSP beat earnings estimates?
Crispr Therapeutics AG beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +5.90%.
CRSP pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors